SAN DIEGO, Sept. 07, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., the company's president and chief executive officer, will participate in a keynote panel at the 2017 World Antimicrobial Resistance Congress being held September 14-15 in Washington, D.C. The interactive panel will focus on a discussion of key challenges for advancing antibiotic development and incentives that can help spur innovation in the…

SAN DIEGO, Aug. 09, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and provided an update on its corporate activities and product pipeline. "We began the second quarter of 2017 by welcoming the financial community to our inaugural Investor Day, in New York, where we described plans for our CD101 and Cloudbreak™ programs and heard presentations from…

Data published in Antimicrobial Agents and Chemotherapy demonstrate CD101 has superior tissue and lesion penetration compared to the current standard of care SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including anti-infective immunotherapies, today announced publication of data from an in vivo study investigating the deep tissue distribution of CD101, Cidara's next-generation echinocandin agent, compared to the current first-line treatment, micafungin, in the setting of intra-abdominal candidiasis (IAC), one of…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will be participating in a panel discussion at the 2017 Infectious Diseases Summit being held July 13-14 in Baltimore, Maryland. The interactive panel will be part of the Summit's 14th Anti-Infectives Partnering & Deal-Making Conference that will focus on the types and availability of economic incentives to spur…

Panel Discussion Will Highlight Urgent Needs and Opportunities in Antifungal Development SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in a panel discussion at the 2017 BIO International Convention being held June 19-22 in San Diego. The panel will focus on the increasing prevalence of fungal infections and antifungal resistance, and highlight the urgent…

Data Highlight Expanded Utility of CD101 for Potential Treatment and Prevention of Serious Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its novel echinocandin antifungal CD101 will be presented at two upcoming, major medical meetings. CD101 abstracts have been accepted for presentation at both ASM Microbe 2017 in New Orleans, Louisiana from June 1-5 and at the 22nd…

SAN DIEGO, May 10, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and product pipeline. "We are excited about the progress we are making on our CD101 IV and Cloudbreak™ programs, which we discussed at our recent investor day," said Jeffrey Stein, Ph.D., president and chief executive officer of…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison, M.D., M.P.H., has been named chief medical officer (CMO) of the company. Dr. Sandison has been serving as acting chief medical officer of Cidara since September 2016. As CMO, he will continue to lead the global clinical development of CD101 IV, Cidara's novel echinocandin antifungal, currently in Phase 2 clinical trials, as well as…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its CloudbreakTM antibacterial immunotherapy CD201 will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria from April 22-25 and at the 2017 Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon from April 26-29. "These presentations highlight…

CARB-X Funding to Advance Novel First-in-Class Bispecific Immunotherapy to Fight Multi-drug Resistant Bacterial Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of its antibiotic immunotherapy, CD201, for the treatment of life-threatening multi-drug resistant (MDR) Gram-negative bacterial infections. CD201 is the first…